Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07001319 · ClinicalTrials.gov registry record · Phase 1
Study of GS-3242 in Participants With HIV-1; Substudy-05
A Phase 1 study of HIV-1-infection, sponsored by Gilead Sciences.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
- 20
- Study locations
NCT07001319: Recruiting Phase 1 study of HIV-1-infection, sponsored by Gilead Sciences.
NCT07001319 is a Phase 1 study of HIV-1-infection that is actively recruiting participants, run by Gilead Sciences. The registered enrollment target is 30 participants, below the 351-participant average among 71 other HIV-1-infection trials with a reported enrollment target (91% lower). The trial reports 20 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07001319, a Phase 1 study of HIV-1-infection, is actively recruiting participants, sponsored by Gilead Sciences.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study is part of a master study. The goal of master protocol (GS-US-544-5905, NCT05585307) is to learn how novel antiretrovirals (medicines that stop the virus from multiplying) affect the human immunodeficiency virus-1 (HIV-1) infection in people living with HIV (PWH). Substudy GS-US-544-5905-05 is to learn more about the study drug GS-3242 in PWH.
Conditions Studied
Interventions
- DRUG GS-3242
- DRUG BVY
- DRUG Standard of Care
Study Locations (20)
Florida
- Midland Florida Clinical Research Center, LLC - DeLand
- AIDS Healthcare Foundation - Northpoint - Fort Lauderdale
- Midway Immunology & Research Center, LLC - Ft. Pierce
- BLISS Health - Orlando
- Orlando Immunology Center, PA - Orlando
- Triple O Research Institute, P.A. - West Palm Beach
California
- Franco Felizarta, MD - Bakersfield
- Ruane Clinical Research Group, Inc - Los Angeles
- Mills Clinical Research - Los Angeles
- Quest Clinical Research - San Francisco
Texas
- Central Texas Clinical Research - Austin
- Prism Health North Texas - Dallas
- North Texas Infectious Diseases Consultant's, P.A. - Dallas
- AXCES Research Group, LLC - El Paso
District of Columbia
- Washington Health Institute - Washington D.C.
Georgia
- Chatham County Health Department - Savannah
Indiana
- Indiana University School of Medicine - Indianapolis
Michigan
- Be Well Medical Center - Berkley
Missouri
- KC CARE Health Center - Kansas City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2025-05-29 |
| Est. Completion | 2027-02 |
| Phase | Phase 1 |
What NCT07001319 shows while recruiting
NCT07001319 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 351-participant average among 71 other HIV-1-infection trials with a reported enrollment target (91% lower).
The record links to 1 condition, with HIV-1-infection appearing as the primary indexed condition, and to 3 interventions - of which GS-3242 is the first listed.
NCT07001319 names 20 study sites across 9 states, led by Florida, California, Texas.
Frequently Asked Questions
What is clinical trial NCT07001319 about?
NCT07001319 is a clinical study titled "Study of GS-3242 in Participants With HIV-1; Substudy-05". This study is part of a master study. The goal of master protocol (GS-US-544-5905, NCT05585307) is to learn how novel antiretrovirals (medicines that stop the virus from multiplying) affect the human immunodeficiency virus-1 (HIV-1) infection in people living with HIV (PWH). Substudy GS-US-544-5905...
What is the current status of trial NCT07001319?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2025-05-29. Estimated completion is 2027-02.
What conditions does trial NCT07001319 study?
This clinical trial studies the following conditions: HIV-1-infection.
What interventions are being tested in trial NCT07001319?
The interventions under investigation include: GS-3242 (DRUG), BVY (DRUG), Standard of Care (DRUG).
Who is sponsoring clinical trial NCT07001319?
This trial is sponsored by Gilead Sciences, which has 504 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07001319 being conducted?
This trial has 20 study locations across California, District of Columbia, Florida, Georgia, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HIV-1-infection
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07001319's enrollment target sits among peer trials
30 58th of 71 higher than 12 of 71 other HIV-1-infection trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other HIV-1-infection trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study of Bictegravir/Emtricitabine/Tenofovir Alafenamide in Newborns Exposed to HIV
RECRUITING · Phase 1
-
Evaluation of Safety, Immunogenicity and Efficacy of a Triple Immune Regimen in Adults Initiated on ART During Acute HIV-1
RECRUITING · Phase 1
-
Study of Oral and Long-Acting Injectable Cabotegravir and Rilpivirine in Virologically Suppressed Children Living With HIV-1, Two to Less Than 12 Years of Age
RECRUITING · Phase 1
-
PET Imaging of Radiolabeled Anti-HIV-1 Envelope Monoclonal Antibody (VRC01)
RECRUITING · Phase 1
-
Safety Study of MucoCept-CVN
RECRUITING · Phase 1
-
A Clinical Trial Investigating the Safety and Biological Activity of the Antibody BNT351 in Adults Living Without and With HIV
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI